PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates ...

The FDA has approved Ketarx, a ketamine-based drug developed by drugmaker PharmaTher, for use in pain management. The medication is now cleared by the FDA for clinical use in perioperative settings, ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company ...

PharmaTher Holdings Ltd ( ($TSE:PHRM) ) just unveiled an update. PharmaTher Holdings Ltd. has received FDA approval for its ketamine product, ...

The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical ...

Real-time index price for Nasdaq Other Finance Index (OFIN), along with buy or sell indicators, analysis, charts, historical ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the research and commercialization of KETARX™ (Ketamine) to fill the unmet medical needs for surgery, pain, mental health ...

PharmaTher Holdings Ltd. PHRRF PHRM is focused on the research, development and commercialization of specialty ketamine prescription-based products including KETAPATCH, a ketamine microneedle ...

PharmaTher Holdings Ltd. PHRRF has published its operational and audited financial results for fiscal year ended May 31, 2022. The company, which focuses on delivering ketamine for treating mental ...

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the research and commercialization of KETARX™ (Ketamine) to fill the unmet medical needs for surgery, pain, mental health ...